1,174 research outputs found
Phase-and-amplitude recovery from a single phase contrast image using partially spatially coherent X-ray radiation
A simple method of phase-and-amplitude extraction is derived that corrects
for image blurring induced by partially spatially coherent incident
illumination using only a single intensity image as input. The method is based
on Fresnel diffraction theory for the case of high Fresnel number, merged with
the space-frequency description formalism used to quantify partially coherent
fields and assumes the object under study is composed of a single material. A
priori knowledge of the object's complex refractive index and information
obtained by characterizing the spatial coherence of the source is required. The
algorithm was applied to propagation-based phase contrast data measured with a
laboratory-based micro-focus X-ray source. The blurring due to the finite
spatial extent of the source is embedded within the algorithm as a simple
correction term to the so-called Paganin algorithm and is also numerically
stable in the presence of noise
The preparticipation cardiovascular screening of competitive athletes: is it time to change the customary clinical practice?
n/
A novel ultrafast-low-dose computed tomography protocol allows concomitant coronary artery evaluation and lung cancer screening
BACKGROUND:Cardiac computed tomography (CT) is often performed in patients who are at high risk for lung cancer in whom screening is currently recommended. We tested diagnostic ability and radiation exposure of a novel ultra-low-dose CT protocol that allows concomitant coronary artery evaluation and lung screening.
METHODS: We studied 30 current or former heavy smoker subjects with suspected or known coronary artery disease who underwent CT assessment of both coronary arteries and thoracic area (Revolution CT, General Electric). A new ultrafast-low-dose single protocol was used for ECG-gated helical acquisition of the heart and the whole chest. A single IV iodine bolus (70-90 ml) was used. All patients with CT evidence of coronary stenosis underwent also invasive coronary angiography.
RESULTS: All the coronary segments were assessable in 28/30 (93%) patients. Only 8 coronary segments were not assessable in 2 patients due to motion artefacts (assessability: 98%; 477/485 segments). In the assessable segments, 20/21 significant stenoses (> 70% reduction of vessel diameter) were correctly diagnosed. Pulmonary nodules were detected in 5 patients, thus requiring to schedule follow-up surveillance CT thorax. Effective dose was 1.3 ± 0.9 mSv (range: 0.8-3.2 mSv). Noteworthy, no contrast or radiation dose increment was required with the new protocol as compared to conventional coronary CT protocol.
CONCLUSIONS:The novel ultrafast-low-dose CT protocol allows lung cancer screening at time of coronary artery evaluation. The new approach might enhance the cost-effectiveness of coronary CT in heavy smokers with suspected or known coronary artery disease
Inhibition of dengue virus replication by novel inhibitors of RNA-dependent RNA polymerase and protease activities
Dengue virus (DENV) is the leading mosquito-transmitted viral infection in the world. With more than 390 million new infections annually, and up to 1 million clinical cases with severe disease manifestations, there continues to be a need to develop new antiviral agents against dengue infection. In addition, there is no approved anti-DENV agents for treating DENV-infected patients. In the present study, we identified new compounds with anti-DENV replication activity by targeting viral replication enzymes – NS5, RNA-dependent RNA polymerase (RdRp) and NS3 protease, using cell-based reporter assay. Subsequently, we performed an enzyme-based assay to clarify the action of these compounds against DENV RdRp or NS3 protease activity. Moreover, these compounds exhibited anti-DENV activity in vivo in the ICR-suckling DENV-infected mouse model. Combination drug treatment exhibited a synergistic inhibition of DENV replication. These results describe novel prototypical small anti-DENV molecules for further development through compound modification and provide potential antivirals for treating DENV infection and DENV-related diseases
THE RISKS AND ADVANTAGES OF ANTI-DIABETES THERAPY IN THE POSITIVE COVID-19 PATIENT
The new Sars-Cov-2 (COVID-19) is causing thousands of deaths worldwide and has caused a global pandemic, one of the biggest health challenges ever faced in history. in the most severe cases, Sars-Cov-2 infection can cause fatal lung injuries. In this context, it is essential to recognise effective therapeutic agents against the virus. There are currently no direct and effective vaccines and antivirals available. People with pre-existing conditions, such as diabetes, and with chronic drug therapies in place may represent complex patients difficult to manage clinically during COVID-19 infection and at high risk of major complications. The regulation of blood glucose and the adoption of appropriate measures are critical aspects to consider for the diabetic patient in this pandemic period, especially in the patient with ongoing infection. In this article we describe the current evidence in the literature on the possible risks of side effects caused by taking antidiabetic drugs in the COVID-19 patient and the data on extra homeostasis glycemic activity useful to fight viral infection.
Peer Review History:
Received 25 May 2020; Revised 8 June; Accepted 3 July, Available online 15 July 2020
Academic Editor: Essam Mohamed Eissa, Beni-Suef University, Egypt, [email protected]
UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.
Received file: Reviewer's Comments:
Average Peer review marks at initial stage: 5.5/10
Average Peer review marks at publication stage: 7.0/10
Reviewer(s) detail:
Dr. Heba M. Abd El-Azim, Damanhour University, Egypt, [email protected]
Dr. George Zhu, Tehran University of Medical Sciences, Tehran, Iran, [email protected]
Similar Articles:
THE RELATIONSHIP BETWEEN DIABETES MELLITUS AND TUBERCULOSIS IN REVIEW OF PREVALENCE, DIAGNOSTICS AND PREVENTIO
USE OF COLCHICINE TO COUNTERACT THE STRONG HYPERINFLAMMATORY STATE INDUCED BY SARS-COV-2
Research in present time has been focusing on finding a specific SARS-CoV-2 vaccine or antiviral, which will probably be the therapeutic goal in the fight against the virus. In the meantime, scientific evidence shows that it is possible to have effective clinical improvements of infected patients in reducing the strong hyperinflammatory state. The SARS-CoV-2 infection is divided into three stages. The most serious phase is the third one where the immune system overdrives and launches an intense attack against itself. This is called "cytokine storm" and leads to tissue damage and often to death. Stopping the cytokine storm early is definitely an effective move; since March several studies have been evaluating how this can be an important pharmacological aspect. Blocking IL-6 or IL-1 inhibitors, for example, is already known to have wide efficacy, but they are not alone in being able to block the cascade of cytokines. This is a clinical pharmacology article and demonstrates how the use of colchicine, monotherapy or in combination in all three phases of SARS-CoV-2, controls inflammation and prevents patient death. Colchicine is safe and effective for treating SARS-CoV-2 patients in preventing inflammation and lung collapse and is certainly useful as an added remedy for other drugs. The advantage is certainly its safety profile much higher than that provided by other drugs, such as corticosteroids and immunosuppressive drugs. Note is the story of hydroxychloroquine: use has been banned due to its high toxicity.
Peer Review History:
Received 25 May 2020; Revised 10 June; Accepted 6 July, Available online 15 July 2020
Academic Editor: Dr. Muhammad Zahid Iqbal, AIMST University, Malaysia, [email protected]
UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.
Received file: Reviewer's Comments:
Average Peer review marks at initial stage: 5.5/10
Average Peer review marks at publication stage: 7.0/10
Reviewer(s) detail:
Dr. Jennifer Audu-Peter, University of Jos, Nigeria, [email protected]
Dr. Robert Tungadi, State University of Gorontalo, Indonesia, [email protected]
Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity
Takotsubo syndrome (TTS) is estimated to account for 1–3% of all patients presenting with suspected ST-segment elevation myocardial infarction. A sudden surge in sympathetic nervous system is considered the cause of TTS. Nonetheless, no specific recommendations have been provided regarding β-blocking therapy. Apart from specific contra-indications (severe LV dysfunction, hypotension, bradycardia and corrected QT interval >500 ms), treatment with a β-blocker seems reasonable until full recovery of LV ejection fraction, though evidence is limited to a few animal studies, case reports or observational studies. In this review, we will reappraise the rationale for β-blocker therapy in TTS and speculate on the pathophysiologic basis for preferring non-selective agents with vasodilating activity over β1-selective drugs
- …